Whitnell & Co’s AstraZeneca AZN Stock Holding History

Whitnell & Co’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-73	Closed	-$5K	–	253
2018 Q2	$5K	Hold	73	–	–	﹤0.01%	259
2018 Q1	$5K	Hold	73	–	–	﹤0.01%	288
2017 Q4	$5K	Buy	+73	New	+$4.92K	﹤0.01%	251
2016 Q4	–	Sell	-156	Closed	-$10K	–	385
2016 Q3	$10K	Buy	+156	New	+$10.2K	﹤0.01%	242
2016 Q2	–	Sell	-187	Closed	-$11K	–	374
2016 Q1	$11K	Buy	187 +65	+53%	+$3.91K	﹤0.01%	231
2015 Q4	$8K	Hold	122	–	–	﹤0.01%	252
2015 Q3	$8K	Buy	+122	New	+$8.03K	﹤0.01%	246

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Whitnell & Co's AZN Position: Q3 2018 in Review

Whitnell & Co sold out of AstraZeneca (AZN) in Q3 2018, closing a stake of 73 shares — an estimated $5K sold.

Whitnell & Co first reported a position in AZN in Q3 2015 and held it in 7 quarters. The position peaked at $11K in Q1 2016. 544 funds tracked by Wall St. Rank hold AZN as of Q3 2018.

Whitnell & Co reported no remaining AstraZeneca position as of Q3 2018 after selling out during the quarter.
Whitnell & Co sold 73 AstraZeneca shares in Q3 2018, an estimated $5K.
Whitnell & Co first reported a position in AstraZeneca in Q3 2015 and held it in 7 quarters.
Whitnell & Co's AstraZeneca position peaked at $11K in Q1 2016.
544 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2018.

Based on Whitnell & Co's 13F filing for Q3 2018, filed 23 Oct 2018.